^
    30d
    PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=53, Terminated, Pfizer | Trial completion date: Nov 2025 --> Jun 2024 | Active, not recruiting --> Terminated; The study was prematurely discontinued due to strategic reasons, not major safety concerns, futility, or requests from any regulatory authorities
    Trial completion date • Trial termination • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive
    |
    Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892
    7ms
    PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=53, Active, not recruiting, Pfizer | N=36 --> 53
    Enrollment change • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive
    |
    Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892
    12ms
    PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=196 --> 36
    Enrollment closed • Enrollment change
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive
    |
    Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892
    over1year
    SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. (PubMed, Cancer Discov)
    PF-07284892 (ARRY-558) is an allosteric SHP2 inhibitor designed to overcome bypass-signaling-mediated resistance when combined with inhibitors of various oncogenic drivers...This provides proof of concept of the utility of SHP2 inhibitors in overcoming resistance to diverse targeted therapies and provides a paradigm for accelerated testing of novel drug combinations early in clinical development. See related commentary by Hernando-Calvo and Garralda.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • KRAS mutation • BRAF V600 • ALK positive • KRAS G12D • ALK fusion • ROS1 fusion • ROS1 positive • KRAS G12
    |
    PF-07284892
    over1year
    PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=196, Recruiting, Pfizer | Trial completion date: Sep 2026 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Jun 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive
    |
    Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892
    over1year
    PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=196, Recruiting, Pfizer | Trial completion date: Apr 2026 --> Sep 2026
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive
    |
    Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892
    over1year
    PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=196, Recruiting, Pfizer | Trial completion date: Feb 2027 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Apr 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive
    |
    Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892
    3years
    PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=211, Recruiting, Pfizer | N=70 --> 211
    Clinical • Enrollment change • Combination therapy
    |
    ALK (Anaplastic lymphoma kinase) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • ROS1 positive
    |
    Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892
    over3years
    PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=70, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    ALK (Anaplastic lymphoma kinase) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • ROS1 positive
    |
    Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892
    over3years
    PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Pfizer
    Clinical • New P1 trial • Combination therapy
    |
    ALK (Anaplastic lymphoma kinase) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • ROS1 positive
    |
    Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892